Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Multihance (gadobenate dimeglumine) and Alcohol / Food Interactions

There is 1 alcohol/food/lifestyle interaction with Multihance (gadobenate dimeglumine):

Major

High Blood Pressure (Hypertension)

Severe Potential Hazard, Moderate plausibility

gadolinium-based contrast agents - renal impairment

Gadolinium-based contrast agents (GBCAs), such as gadobutrol, gadobenate dimeglumine, and gadoterate meglumine increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Gadobenate ion is eliminated predominately via the kidneys. The risk for NSF appears highest among patients with chronic, severe kidney disease (GFR <30 mL/min/1.73m2), or acute kidney injury. It is recommended to avoid the use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other processes. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. Consider screening patients for acute kidney injury and other conditions that may reduce renal function and for patients at risk for chronically reduced renal function (e.g., age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. For patients receiving hemodialysis, physicians may consider the prompt initiation of hemodialysis following the administration of a GBCA to enhance the contrast agent's elimination. The usefulness of hemodialysis in the prevention of NSF is unknown.

Multihance (gadobenate dimeglumine) drug interactions

There are 70 drug interactions with Multihance (gadobenate dimeglumine)

Multihance (gadobenate dimeglumine) disease interactions

There is 1 disease interaction with Multihance (gadobenate dimeglumine):

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide